News Release 

Identifying potential anti-COVID-19 pharmacological components of TCM

Compuscript Ltd

Research News

IMAGE

IMAGE: This study provides chemical and biochemical evidence of LHQW capsule for the treatment of COVID-19 patients based on the components exposed to human. view more 

Credit: Acta Pharmaceutica Sinica B

Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to LHQW components and their pharmacological effects remain largely unknown. The authors of this study aimed to determine human exposure to LHQW components. Based on the human exposure analysis, several ACE2 binding components with good enzyme inhibitory effects were screened out by ACE2 biochromatography. The results obtained by the authors demonstrated chemical and biochemical evidence for exploring molecular mechanisms of therapeutic effects of LHQW capsule for the treatment of COVID-19 patients based on the components exposed to humans.

The research also demonstrated the utility of the human exposure-based approach to identifying pharmaceutically active components in Chinese herb medicines.

###

Article reference: Xiaofei Chen, Yunlong Wu, Chun Chen, Yanqiu Gu, Chunyan Zhu, Suping Wang, Jiayun Chen, Lei Zhang, Lei Lv, Guoqing Zhang, Yongfang Yuan, Yifeng Chai, Mingshe Zhu and Caisheng Wu, Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening, Acta Pharmaceutica Sinica B, 2020, ISSN 2211-3835, https://doi.org/10.1016/j.apsb.2020.10.002

Keywords: Lianhuaqingwen capsule, PATBS, COVID-19, ACE2, Biochromatography, Comprehensive 2D analysis, In vivo exposure, Surface plasma response, Molecular docking

The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.

Acta Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences -- including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.

For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/

Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board

APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).

Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).

CiteScore: 10.5

Impact Factor: 7.097

5-Year Impact Factor: 7.865

Source Normalized Impact per Paper (SNIP): 2.210

SCImago Journal Rank (SJR): 1.792

ISSN 2211-3835

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.